Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD BeovuⓇ - VEGF Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT04278417 (CRTH258D2301) Diabetic retinopathy Phase 3 706 Change from Baseline in BCVA Arm 1: RTH258 (Brolucizumab) 6 mg3 x q6w loading injections, followed by q12w maintenance through week 90 Arm 2: Panretinal photocoagulation laser initial treatment in 1-4 sessions up to Week 12, followed with additional PRP treatment as needed Patients with proliferative diabetic retinopathy Target Patients Read-out Milesstone(s) 2024 Publication TBD 99 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation